Imunon's Ovarian Cancer Drug Advances to Phase 3, Showing Strong Early Efficacy

Ticker: IMNN · Form: 10-K · Filed: Mar 31, 2026 · CIK: 0000749647

Sentiment: mixed

Topics: Biotechnology, Ovarian Cancer, Immunotherapy, Clinical Trials, DNA Vaccines, Oncology, Drug Development

Related Tickers: IMNN

TL;DR

**IMNN is a high-risk, high-reward biotech play with a promising ovarian cancer drug entering Phase 3, but its success hinges entirely on clinical trial outcomes and future funding.**

AI Summary

Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing non-viral DNA technology for innovative treatments. The company's lead program, IMNN-001, an immunotherapy for advanced ovarian cancer, is currently in a Phase 3 clinical trial (OVATION 3) after completing a Phase 2 trial (OVATION 2). IMNN-001 works by locally producing interleukin-12 and interferon gamma at the tumor site. The OVATION 1 Study, a Phase 1 trial, showed promising results with a 100% disease control rate and an 86% objective response rate among 14 patients, including a 100% objective response rate in the highest dose cohort. Furthermore, 64% of patients achieved a complete tumor resection (R0), with all five patients in the highest dose cohort achieving R0. The company also completed dosing for IMNN-101, a COVID-19 booster vaccine, in a first-in-human study. Imunon's technology platform is optimized for DNA and mRNA therapeutics delivery via synthetic non-viral carriers, aiming for enhanced molecular versatility and a favorable safety profile compared to naked DNA or cationic lipids.

Why It Matters

Imunon's progress with IMNN-001 in ovarian cancer is significant for investors, as successful Phase 3 trials could lead to market approval and substantial revenue in a disease with high unmet need. For patients, particularly those with platinum-resistant ovarian cancer where current therapies have only 10-20% response rates and 11-12 months median overall survival, IMNN-001 offers a potentially life-extending alternative. The company's non-viral DNA technology could also disrupt the gene therapy market by offering a safer, more cost-effective alternative to viral vectors, challenging competitors in the oncology and infectious disease spaces. This could attract partnerships and further investment, impacting the broader biotechnology market.

Risk Assessment

Risk Level: high — Imunon is a clinical-stage biotechnology company with no approved products and relies entirely on the success of its drug candidates, IMNN-001 and IMNN-101. The company's market value of common stock held by non-affiliates was approximately $21.2 million as of June 30, 2025, indicating a relatively small capitalization for a company undertaking Phase 3 trials, which are expensive and carry significant risk of failure. The filing explicitly lists 'unforeseen changes in the course of research and development activities and in clinical trials' and 'our ability to obtain additional funds for our operations' as key risk factors.

Analyst Insight

Investors should approach IMNN with extreme caution, recognizing the binary nature of clinical-stage biotech investments. Monitor the progress of the OVATION 3 study closely and assess the company's ability to secure additional financing, as these will be critical determinants of its future viability.

Financial Highlights

debt To Equity
Not Disclosed
revenue
Not Disclosed
operating Margin
Not Disclosed
total Assets
Not Disclosed
total Debt
Not Disclosed
net Income
Not Disclosed
eps
Not Disclosed
gross Margin
Not Disclosed
cash Position
Not Disclosed
revenue Growth
Not Disclosed

Key Numbers

Key Players & Entities

FAQ

What is Imunon's lead drug candidate and what disease does it target?

Imunon's lead drug candidate is IMNN-001, a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. It works by instructing the body to produce cancer-fighting molecules like interleukin-12 and interferon gamma at the tumor site.

What were the key efficacy results from the OVATION 1 Study for IMNN-001?

The OVATION 1 Study showed a 100% disease control rate and an 86% objective response rate (ORR) among 14 patients. In the highest dose cohort, all five patients achieved a 100% ORR and a 100% complete tumor resection (R0) surgical resection.

What is the current clinical trial phase for Imunon's IMNN-001?

IMNN-001 is currently conducting a Phase 3 clinical trial, known as the OVATION 3 Study, for the localized treatment of advanced ovarian cancer.

What is Imunon's other significant drug candidate besides IMNN-001?

Imunon's other significant drug candidate is IMNN-101, a COVID-19 booster vaccine. The company has completed dosing in a first-in-human study for IMNN-101.

What are the primary risks associated with investing in Imunon, Inc.?

Primary risks include the inherent uncertainties of clinical trials, the need for additional funding for operations, and the highly competitive and regulated biotechnology environment. The company's small market capitalization of approximately $21.2 million as of June 30, 2025, also highlights its vulnerability.

How does IMNN-001's mechanism of action differ from conventional ovarian cancer therapies?

IMNN-001 is a DNA-based immunotherapy that locally produces interleukin-12 (IL-12) and interferon gamma at the tumor site, aiming to create a potent immune environment against tumor activity. This differs from conventional chemotherapy or targeted agents like PARP inhibitors by leveraging the body's immune system directly at the tumor site.

What is the significance of the 'R0 surgical resection' rate reported in the OVATION 1 Study?

An R0 surgical resection indicates a microscopically margin-negative resection where no gross or microscopic tumor remains in the tumor bed. The 64% R0 rate (and 100% in the highest dose cohort) in the OVATION 1 Study suggests a strong potential for IMNN-001 to improve surgical outcomes for ovarian cancer patients.

What is Imunon's technology platform focused on?

Imunon's technology platform is optimized for the delivery of DNA and mRNA therapeutics via synthetic non-viral carriers. It is designed to provide cell transfection for double-stranded DNA plasmids and large therapeutic RNA segments, aiming for enhanced molecular versatility, efficiency, and a favorable safety profile.

What is the market value of Imunon's common stock held by non-affiliates?

As of June 30, 2025, the aggregate market value of Imunon's common stock held by non-affiliates was approximately $21.2 million, based on a closing sale price of $10.43 per share.

Why is ovarian cancer considered a challenging disease to treat?

Ovarian cancer is considered the most lethal gynecological malignancy, with over 60% of women dying within five years of diagnosis, largely due to late diagnosis at Stages III or IV. Mortality rates have declined very little in 40 years, and platinum-resistant cases have limited treatment options with low response rates (10-20%) and short median overall survival (11-12 months).

Risk Factors

Industry Context

Imunon operates in the highly competitive clinical-stage biotechnology sector, focusing on oncology and infectious disease. The company's non-viral DNA and mRNA delivery platform positions it within the rapidly evolving field of advanced therapeutics. Key industry trends include the increasing focus on personalized medicine, immunotherapy, and novel drug delivery systems, driven by significant unmet medical needs in areas like advanced ovarian cancer.

Regulatory Implications

Imunon's development programs are subject to stringent regulatory oversight by agencies like the FDA. The success of IMNN-001 hinges on demonstrating safety and efficacy through rigorous clinical trials (OVATION 3) to gain regulatory approval. Any delays or adverse findings in these trials could significantly impact the company's ability to bring its products to market.

What Investors Should Do

  1. Monitor OVATION 3 trial progress and interim data releases.
  2. Assess Imunon's cash burn rate and future financing needs.
  3. Evaluate competitive landscape and potential market penetration for IMNN-001.
  4. Review any updates on the IMNN-101 COVID-19 booster vaccine program.

Glossary

Phase 3 clinical trial
The final stage of clinical drug development, involving a large number of patients to confirm efficacy, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely. (Imunon's lead program, IMNN-001, is in a Phase 3 trial (OVATION 3), which is critical for potential market approval.)
Disease Control Rate (DCR)
The percentage of patients in a clinical trial whose cancer did not progress (i.e., remained stable, partially responded, or completely responded) after treatment. (A 100% DCR in the OVATION 1 Study for IMNN-001 suggests strong initial efficacy in controlling tumor growth.)
Objective Response Rate (ORR)
The percentage of patients in a clinical trial whose cancer showed a significant reduction in size or disappeared completely in response to treatment. (An 86% ORR in the OVATION 1 Study, with 100% in the highest dose cohort, indicates substantial tumor shrinkage in patients treated with IMNN-001.)
Complete Tumor Resection (R0)
A surgical outcome where all visible cancerous tissue is removed during surgery, with no microscopic evidence of cancer left behind. (A 64% R0 rate in the OVATION 1 Study, with 100% in the highest dose cohort, is a significant indicator of IMNN-001's potential to facilitate curative surgery.)
Interleukin-12 (IL-12)
A cytokine that plays a role in the immune system's response to pathogens and cancer, often used in cancer immunotherapy to stimulate T-cell and NK cell activity. (IMNN-001 works by locally producing IL-12 at the tumor site, aiming to activate an anti-tumor immune response.)
Interferon gamma (IFN-γ)
Another cytokine that enhances the immune response, particularly against viruses and tumors, by activating immune cells and influencing gene expression. (IMNN-001 also locally produces IFN-γ, contributing to the anti-tumor immune environment.)
Non-viral DNA technology
A method of delivering genetic material (like DNA or mRNA) into cells using synthetic carriers that are not derived from viruses, aiming for improved safety and versatility. (This is the core technology platform for Imunon's therapeutic candidates, including IMNN-001.)

Year-Over-Year Comparison

Specific comparative metrics to the previous year's filing (e.g., revenue, net income, operating expenses) are not available from the provided text. However, the company's focus on advancing IMNN-001 into a Phase 3 trial suggests significant investment in research and development, likely leading to increased operating expenses compared to prior periods. New risks related to the progression of late-stage clinical trials and ongoing capital requirements would be more prominent in the current filing.

Filing Stats: 4,417 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2026-03-31 08:50:51

Key Financial Figures

Filing Documents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 1 OVERVIEW 2 THERAPLAS MODALITY: IMNN-001 DEVELOPMENT PROGRAM 2 Ovarian Cancer Overview 2 IMNN-001 Immunotherapy 3 OVATION I Study 3 OVATION 2 Study 5 OVATION 3 Study 8 IMNN-001 in Combination with Bevacizumab 9 PLACCINE DNA VACCINE MODALITY: IMNN-101 9 Our Next Generation Vaccine Initiative 10 BUSINESS STRATEGY AND DEVELOPMENT PLAN 12 RESEARCH AND DEVELOPMENT EXPENDITURES 13 GOVERNMENT REGULATION 14 MANUFACTURING AND SUPPLY 24 SALES AND MARKETING 24 PRODUCT LIABILITY AND INSURANCE 25 COMPETITION 25 INTELLECTUAL PROPERTY 26 Patents and Proprietary Rights 26 EMPLOYEES 27 COMPANY INFORMATION 28 AVAILABLE INFORMATION 28 ITEM 1A.

RISK FACTORS

RISK FACTORS 28 ITEM 1B. UNRESOLVED STAFF COMMENTS 43 ITEM 1C. CYBERSECURITY 43 ITEM 2.

PROPERTIES

PROPERTIES 44 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 44 ITEM 4. MINE SAFETY DISCLOSURES 44 i IMUNON, INC. FORM 10-K TABLE OF CONTENTS (continued) PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 45 Market for Our Common Stock 45 Record Holders 45 Dividend Policy 45 Performance Graph 45 Issuer Purchases of Equity Securities 45 ITEM 6. RESERVED 45 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 45 Overview 46 Business Plan 46 Financing Overview 47 Critical Accounting Policies and Estimates 49 Results of Operations 50 Financial Condition, Liquidity and Capital Resources 52 Off-Balance Sheet Arrangements 52 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 52 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 52 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 53 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 53 ITEM 9B. OTHER INFORMATION 53 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 53 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 54 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 58 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 63 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 66 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 66 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 67 1. FINANCIAL STATEMENTS 67 2. FINANCIAL STATEMENT SCHEDULES 67 3. EXHIBITS 67 ITEM 16. FORM 10-K SUMMARY 69 ii ITEM 1.

BUSINESS

BUSINESS FORWARD-LOOKING Certain of the statements contained in this Annual Report on Form 10-K ("Annual Report") are forward-looking and constitute forward-looking of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements may relate to such matters as anticipated financial performance, business prospects, technological developments, product pipelines, clinical trials and research and development activities, the adequacy of capital reserves and anticipated operating results and cash expenditures, current and potential collaborations, strategic alternatives and other aspects of our present and future business operations and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among other things, unforeseen changes in the course of research and development activities and in clinical trials; possible changes in cost, timing and progress of development, preclinical studies, clinical trials and regulatory submissions; our collaborators' ability to obtain and maintain regulatory approval of any of our drug candidates; possible changes in capital structure, financial condition, future working capital needs and other financial items; uncertainties and assumptions regarding the potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the Russian invasion of Ukraine a

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing